Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Kaposi 1Respiratory Distress Syndrome 1Pneumonia 1Multi-centric Castleman's Disease 1Hematologic Neoplasms 1Glioblastoma 1Castleman Disease 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Temozolomide 22Radiotherapy 17Carmustine 9Magnetic Resonance Spectroscopy 8Carboplatin 8Vorinostat 6Surgical Procedures, Operative 6Radiation 6Cisplatin 6Chemotherapy, Adjuvant 6O(6)-benzylguanine 5Erlotinib Hydrochloride 5Cyclophosphamide 5Bevacizumab 5veliparib 4Vincristine 4Thiotepa 4Specimen Handling 4Radiotherapy, Intensity-Modulated 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Lenalidomide 4Filgrastim 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4Radiotherapy, Conformal 3Procarbazine 3Lomustine 3Iodine-125 3Immunoglobulin G 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Astrocytoma × tocilizumab × Clear all
NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡